MustGrow Biologics Past Earnings Performance
Past criteria checks 0/6
MustGrow Biologics's earnings have been declining at an average annual rate of -8.9%, while the Chemicals industry saw earnings growing at 17.5% annually. Revenues have been growing at an average rate of 97.8% per year.
Key information
-8.9%
Earnings growth rate
2.6%
EPS growth rate
| Chemicals Industry Growth | 12.4% |
| Revenue growth rate | 97.8% |
| Return on equity | -11.3% |
| Net Margin | -9.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How MustGrow Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5 | 0 | 4 | 1 |
| 31 Mar 24 | 5 | -1 | 4 | 1 |
| 31 Dec 23 | 5 | -1 | 4 | 1 |
| 30 Sep 23 | 0 | -5 | 4 | 1 |
| 30 Jun 23 | 0 | -5 | 4 | 1 |
| 31 Mar 23 | 0 | -6 | 4 | 1 |
| 31 Dec 22 | 0 | -6 | 4 | 0 |
| 30 Sep 22 | 0 | -6 | 4 | 1 |
| 30 Jun 22 | 0 | -4 | 3 | 0 |
| 31 Mar 22 | 0 | -3 | 2 | 0 |
| 31 Dec 21 | 0 | -3 | 2 | 0 |
| 30 Sep 21 | 0 | -3 | 2 | 0 |
| 30 Jun 21 | 0 | -3 | 2 | 0 |
| 31 Mar 21 | 0 | -3 | 3 | 0 |
| 31 Dec 20 | 0 | -3 | 3 | 0 |
| 30 Sep 20 | 0 | -3 | 3 | 0 |
| 30 Jun 20 | 0 | -3 | 2 | 0 |
| 31 Mar 20 | 0 | -2 | 2 | 0 |
| 31 Dec 19 | 0 | -2 | 1 | 0 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | -1 | 1 | 0 |
| 31 Mar 19 | 0 | -1 | 1 | 0 |
| 31 Dec 18 | 0 | -2 | 1 | 0 |
| 30 Sep 18 | 0 | -2 | 1 | 0 |
| 30 Jun 18 | 0 | -1 | 1 | 0 |
| 31 Mar 18 | 0 | -1 | 1 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
| 31 Dec 15 | 0 | -1 | 0 | 0 |
Quality Earnings: 0C0 is currently unprofitable.
Growing Profit Margin: 0C0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0C0 is unprofitable, and losses have increased over the past 5 years at a rate of 8.9% per year.
Accelerating Growth: Unable to compare 0C0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0C0 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-16.5%).
Return on Equity
High ROE: 0C0 has a negative Return on Equity (-11.32%), as it is currently unprofitable.